Table 2.
Cardiovascular safety markers, part I
| Variable | T1 | T2 | T3 | Time*group | Time*group*gender |
|---|---|---|---|---|---|
| SBP (mm Hg) | |||||
| PLA | 117 ± 15 | 116 ± 12 | 115 ± 13 | Time p = 0.45 | G*T*Ge p = 0.73 |
| LD | 116 ± 9 | 115 ± 8 | 116 ± 6 | G*T p = 0.12 | |
| HD | 118 ± 15 | 124 ± 12 | 122 ± 13 | ||
| DBP (mm Hg) | |||||
| PLA | 69 ± 9 | 68 ± 9 | 68 ± 9 | Time p = 0.58 | G*T*Ge p = 0.89 |
| LD | 70 ± 7 | 67 ± 8 | 71 ± 8 | G*T p = 0.53 | |
| HD | 70 ± 8 | 68 ± 8 | 73 ± 8 | ||
| Heart rate (beats/min) | |||||
| PLA | 60 ± 10 | 64 ± 8 | 63 ± 10 | Time p = 0.032 | G*T*Ge p = 0.85 |
| LD | 60 ± 15 | 59 ± 10a | 63 ± 12a | G*T p = 0.35 | |
| HD | 59 ± 12 | 63 ± 10 | 64 ± 13 | ||
| Vent Rate (breath/min) | |||||
| PLA | 60 ± 9 | 61 ± 10 | 62 ± 8 | Time p = 0.43 | G*T*Ge p = 0.67 |
| LD | 57 ± 13 | 59 ± 11 | 60 ± 13 | G*T p = 0.10 | |
| HD | 63 ± 12 | 59 ± 11 | 61 ± 11 | ||
Abbreviations: PLA Placebo, LD Theacrine Low Dose, HD Theacrine High Dose, G Group, T Time, Ge Gender
Superscript letters, different letters are significantly different at a given time point (p < 0.05). Items in bold indicate a significant effect (p < 0.05) was observed